Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Excessive Ca2+ currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg2+, NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca2+ determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg2+ and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg2+, tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone is a new, noncompetitive NMDAR antagonist 475 that exhibits fast antidepressant-like action by improving performance of rats in the forced swim test. 476”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [475]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical research found that REL-1017 preferentially binds to the NR1-2D subunit [182]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“NP_015566 corresponds to the NR1-1a splice variant [42] lacking the N1 cassette but including C1 and C2 cassettes.”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“REL-1017 (esmethadone HCl; dextromethadone HCl), the d-isomer of racemic methadone, is a low-affinity, low-potency, uncompetitive NMDAR channel blocker, devoid of meaningful opioid agonist effects [12] with experimental evidence for producing brain-derived neurotrophic factor (BDNF) and target of rapamycin complex 1 (…”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
A Brief History of Long-Term Potentiation
Nicoll, R. A. (2017) · Neuron · doi:10.1016/j.neuron.2016.12.015 · Cited by 841
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
Laurel Gorman, A., Elliott, K. J., & Inturrisi, C. E. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13391-2 · Cited by 398
Self-citationAllosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 363
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Sutton, M. A., Taylor, A. M., Ito, H. T., Pham, A., & Schuman, E. M. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.030 · Cited by 274
Mg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Multiple Structural Elements Determine Subunit Specificity of Mg2+Block in NMDA Receptor Channels
Kuner, T., & Schoepfer, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-11-03549.1996 · Cited by 235 · cited 5×
“In the presence of physiological concentrations of Mg2+ at resting membrane potentials, persistent tonic Ca2+ currents are seen preferentially via NR1-2C and NR1-2D subtypes [1,17] due to their lower affinity for Mg2+ compared to NR1-2A and NR1-2B subtypes [23].”
BackgroundResultInfluentialBiased signalling and allosteric machines: new vistas and challenges for drug discovery
Kenakin, T. P. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01749.x · Cited by 233
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Structural basis of ketamine action on human NMDA receptors
Zhang, Y., Ye, F., Zhang, T., Lv, S., Zhou, L., Du, D., Lin, H., Guo, F., Luo, C., & Zhu, S. (2021) · Nature · doi:10.1038/s41586-021-03769-9 · Cited by 218
The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.006 · Cited by 198
Bettini, E., Sava, A., Griffante, C., Carignani, C., Buson, A., Capelli, A. M., Negri, M., Andreetta, F., Senar, S., Guiral, L., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172544 · Cited by 142
Self-citationTabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140 · cited 14×
“Although temporary dissociative effects occur in most patients treated with racemic ketamine and esketamine at doses currently used to treat MDD, the current consensus is that induction of dissociative effects is not necessary for the rapid antidepressant effects of ketamine [37,38].”
BackgroundInfluentialUnmasking GluN1/GluN3A excitatory glycine NMDA receptors
Grand, T., Gerges, S. A., David, M., Diana, M. A., & Paoletti, P. (2018) · Nature Communications · doi:10.1038/s41467-018-07236-4 · Cited by 118
Structural Basis of Functional Transitions in Mammalian NMDA Receptors
Chou, T.-H., Tajima, N., Romero-Hernandez, A., & Furukawa, H. (2020) · Cell · doi:10.1016/j.cell.2020.05.052 · Cited by 117
Mealing, G. A. R., Lanthorn, T. H., Murray, C. L., Small, D. L., & Morley, P. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37943-1 · Cited by 102
Determinants of trapping block of N‐methyl‐d‐aspartate receptor channels
Bolshakov, K. V., Gmiro, V. E., Tikhonov, D. B., & Magazanik, L. G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01956.x · Cited by 96
NR2 subunit‐dependence of NMDA receptor channel block by external Mg2+
Qian, A., Buller, A. L., & Johnson, J. W. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.076737 · Cited by 95
Hanson, E., Armbruster, M., Lau, L. A., Sommer, M., Klaft, Z., Swanger, S. A., Traynelis, S. F., Moss, S. J., Noubary, F., Chadchankar, J., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1392-18.2019 · Cited by 93
Wozniak, D. F., Dikranian, K., Ishimaru, M. J., Nardi, A., Corso, T. D., Tenkova, T., Olney, J. W., & Fix, A. S. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0206 · Cited by 89
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83
Self-citationFogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82
NMDA Receptor Activation by Spontaneous Glutamatergic Neurotransmission
Espinosa, F., & Kavalali, E. T. (2009) · Journal of Neurophysiology · doi:10.1152/jn.90754.2008 · Cited by 77
NMDA antagonists under investigation for the treatment of major depressive disorder
Pochwat, B., Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., & Nowak, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918951 · Cited by 52
A Meta-Analysis of Memantine for Depression
Kishi, T., Matsunaga, S., & Iwata, N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161251 · Cited by 49
Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine
Ide, S., Ikekubo, Y., Mishina, M., Hashimoto, K., & Ikeda, K. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.11.001 · Cited by 47
Bernstein, G., Davis, K., Mills, C., Wang, L., McDonnell, M., Oldenhof, J., Inturrisi, C., Manfredi, P. L., & Vitolo, O. V. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001035 · Cited by 37
Self-citationMealing, G. A. R., Lanthorn, T. H., Small, D. L., Murray, R. J., Mattes, K. C., Comas, T. M., & Morley, P. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29614-2 · Cited by 37
Morris, P. J., Burke, R. D., Sharma, A. K., Lynch, D. C., Lemke-Boutcher, L. E., Mathew, S., Elayan, I., Rao, D. B., Gould, T. D., Zarate, C. A., et al. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.106993 · Cited by 36
Pharmacological Implications of the Conformation of the Methadone Base
Bürgi, H., Dunitz, J. D., & Shefter, E. (1973) · Nature New Biology · doi:10.1038/newbio244186b0 · Cited by 28
De Martin, S., Gabbia, D., Folli, F., Bifari, F., Fiorina, P., Ferri, N., Stahl, S., Inturrisi, C. E., Pappagallo, M., Traversa, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671859 · Cited by 28 · cited 5×
“antidepressant-like effects in animal models [9], increase serum BDNF [35], and rapidly improve MDD in patients [13].”
BackgroundSelf-citationOverview of Receptor Interactions of Agonists and Antagonists
Kenakin, T. (2008) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0401s42 · Cited by 23
Bifari, F., Pappagallo, M., Bleavins, M. R., Traversa, S., Folli, F. B., & Manfredi, P. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863959 · Cited by 12
Self-citationMartin, S. D., Colognesi, M., Inturrisi, C. E., Mattarei, A., Bettini, E., Pappagallo, M., Folli, F. B., Stahl, S. M., Traversa, S., & Manfredi, P. L. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.953 · Cited by 3
Self-citation
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Fava, M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
Self-citationStahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Pani, L., Guidetti, C., Folli, F. B., de Somer, M., Traversa, S., Inturrisi, C. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012196 · Cited by 24
Self-citation
Metadata
- Authors
- Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., Bifari, F., Cavalli, A., Alimonti, A., Pani, L., Fava, M., Traversa, S., Folli, F., & Manfredi, P. L.
- Affiliations
- Aptuit (Italy) (IT)
- University of California San Diego (US)
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
- University of Padua (IT)
- Institute for Research in Biomedicine (CH)
- Albert Einstein College of Medicine (US)
- Relmada Therapeutics, Inc. (United States) (US)
- University of Milan (IT)
- SIB Swiss Institute of Bioinformatics (CH)
- University of Modena and Reggio Emilia (IT)
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
- Corresponding author
- Manfredi, Paolo L.
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-08-13
- Volume
- 15
- Issue
- 8
- Pages
- 997
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9414551
- OpenAlex
- W4291512787
- Cited by
- 31
- References
- 48
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 7 · 2022: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- ETH Zürich Research Collection
- Funders
- Relmada Therapeutics (VDD9974)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- NMDA receptor antagonists, major depressive disorder, dextromethorphan, memantine, ketamine, MK-801, calcium current, open channel conformation, drug binding affinity, psychotomimetic side effects, glutamate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.